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In this issue of Critical Care, Vogelzang and coworkers [1]
present the results of a retrospective study in which they
assessed the relationship between a derivative marker of
blood glucose control, which they label ‘the hyperglycaemic
index’ (HGI), and patient outcome in a 12-bed surgical
intensive care unit (ICU). They define the HGI as the area
under the curve (AUC) of blood glucose above the cutoff of
6.0 mmol/l, divided by the length of ICU stay. They report that
the HGI predicts 30-day mortality better than do other
indices of blood glucose control, such as blood glucose on
admission, mean blood glucose, mean morning blood
glucose and maximal blood glucose level. Those investigators
thus conclude that the HGI is a useful tool with which to
assess glucose control in the ICU patient.
The study aimed to address two questions at once. First,
Vogelzang and coworkers investigated the value of the HGI –
a marker of duration as well as severity of hyperglycaemia
during intensive care – as a predictor of ICU mortality, and
compared it with other indices of blood glucose control that
do not take time into account. Second, the authors planned to
assess this HGI as a tool for comparing adequacy of titration
algorithms in reaching a preset level of glucose control in the
ICU. Unfortunately, however, the study was not in my view
designed to answer this more relevant second question.
The HGI was calculated retrospectively from charts of 1779
patients who had been admitted to the authors’ ICU over the
preceding 12 years. This retrospective analysis inevitably did
not have a predefined sampling interval for blood glucose
measurement or a preset insulin titration algorithm. The
statistical association between the HGI and mortality at
30 days was studied in univariate analyses, and its predictive
potential was compared with those of other measures of
blood glucose control (blood glucose on admission, mean
blood glucose, mean morning blood glucose and maximal
blood glucose level) in multivariate analyses. The authors
confirmed the findings of previous studies [2,3] that
persistence of hyperglycaemia during intensive care
performed better than measures of blood glucose control that
do not take time into account, but which have previously been
shown to predict ICU mortality [4,5]. However, the receiver
operating characteristic (ROC) curve of the HGI revealed an
AUC of only 0.64, indicating that capacity to predict mortality
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Abstract
Vogelzang et al. retrospectively assessed a derivative marker of blood glucose control over time in the
intensive care unit (ICU), “the hyperglycemic index” (HGI), in relation to outcome. The HGI predicted
mortality better than other indices of blood glucose control that do not take the duration of hyper-
glycemia into account. This provided further support to the concept of maintaining normoglycemia with
insulin throughout intensive care in order to improve outcome. The HGI was also proposed as a tool to
assess performance of glucose control algorithms. This, however, implies similar sampling frequency
for the compared algorithms. Just as we prefer continuous, online display of blood pressure and/or
cardiac output for optimal titration of inotropes and vasopressors, a continuous display of blood
glucose levels is mandatory for optimal titration of insulin therapy in ICU. We anxiously await the
development and validation of such devices.
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was relatively poor although perhaps statistically a little better
than for the other markers of blood glucose control. Whatever
the cutoff level for ‘normality’ in intensive care patients was
chosen, the AUC of the ROC remained below 0.65 and thus
remained a poor predictor as compared with other
paramaters. For example, Acute Physiology and Chronic
Health Evaluation II score or serum insulin-like growth factor
binding protein 1 concentration both have AUCs of the ROC
of about 0.8 (the latter being an indicator of hepatic insulin
resistance or lack of insulin effect on the liver) [6].
The statistical association between the HGI – an index of
glycaemic control over time – and mortality provided further
support to the concept of controlling blood glucose to
normal with insulin titration throughout the ICU stay in order
to improve outcome [2,7]. It is precisely this which was
proven by our large, prospective, randomized and controlled
study [7], in which we titrated intensive insulin therapy to
maintain a blood glucose below 6.1 mmol/l throughout
intensive care. The observation by Vogelzang and coworkers
[1] of a slightly better AUC of the ROC when the HGI used a
cutoff of 6–8 mmol/l as compared with 4–6 mmol/l does not
provide evidence supporting use of a higher target of blood
glucose control in the ICU. Indeed, such a differentiation
between targets can only be evaluated in a randomized
controlled interventional study. The Leuven study [7,8] clearly
showed that infusing insulin targeted at an average morning
blood glucose of 5.7 mmol/l reduced mortality and morbidity
as compared with the control group (average morning blood
glucose 8.5 mmol/l). An intermediate level of blood glucose
was found to be inferior to a target of below 6.1 mmol/l in
terms of the effect on morbidity as well as mortality [8].
In order to achieve normoglycaemia during intensive care,
most ICUs require a titration algorithm, particularly during the
start-up phase when it is introduced to the nursing staff. If the
performance of such algorithms is to be assessed, then a tool
for objectively evaluating the adequacy of blood glucose
control is indeed mandatory. Vogelzang and coworkers [1]
propose that the HGI is such a tool. They claim that the HGI
takes into account the unequal distribution of glucose
sampling and is not falsely lowered by low glucose values.
There are, however, some conditions to be satisfied before
the HGI can be considered as a suitable tool to compare
adequacy of glucose control algorithms. A first condition is
that the blood glucose profile, on which the HGI is calculated,
is one with a relatively high number of blood glucose
measurements, ideally a continuous or close to continuous
blood glucose reading over time. Secondly, in order to
compare blood glucose control in two patient groups using
the HGI, the sampling interval in the two groups should be
comparable. Indeed, when the number of measurements is
reduced, this can dramatically alter the HGI, depending on the
variability in the blood glucose profile. Let us take a theoretical
example of a blood glucose profile following a sinusoid curve
crossing the target line of 6.0 mmol/l four times over a certain
time period, with dramatically raised levels for half of the time.
On multiple sampling, this pattern would be evident, and an
elevated HGI would be calculated. However, if the blood
samples were taken infrequently, for example only four times
and by chance only at the time points when the blood glucose
level crossed the target line, then calculation of HGI would
yield a falsely normal value.
Just as we prefer a continuous, online display of blood
pressure and/or cardiac output for optimal titration of
inotropes and vasopressors, a continuous blood glucose
measurement and display of blood glucose levels would be
of tremendous value in the titration of insulin therapy.
Unfortunately, no such devices are yet available to measure
glucose in the blood, and currently available devices
designed to measure glucose in the subcutaneous adipose
tissue still require validation in the ICU setting. Availability
and validation of such devices will render intensive insulin
therapy easier and safer. Closed loop systems, with
computer-assisted titration of insulin dose, will go a step
further, and this will also reduce nursing workload and further
lower the risk for hypoglycaemia. We anxiously await the
arrival of such devices and their ability to optimize life-saving
intensive insulin therapy in the ICU. Until this becomes a
reality, insulin titration algorithms should include frequent
measurement of blood glucose, which implies adequate
training of the nursing team. After all, it is the members of the
nursing team who have proven to be the most proficient in
executing this task.
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